Zoetis Launches Groundbreaking AI Tool for Faster Cancer Detection in Pets
Zoetis Inc., a global leader in animal health, has unveiled its latest breakthrough in veterinary diagnostics: AI Masses, a powerful new feature on the Vetscan Imagyst® analyzer that delivers rapid, in-clinic screening of lymph node and skin/subcutaneous lesions. Designed to identify potentially neoplastic (cancerous) cells with high accuracy, this technology significantly enhances the ability of veterinary professionals to make fast, informed decisions during critical patient evaluations.
With the addition of AI Masses, the Vetscan Imagyst platform becomes the most capable veterinary artificial intelligence (AI) analyzer currently available, offering a total of seven unique testing applications. The tool supports real-time analysis, providing results in minutes and dramatically accelerating the diagnostic process. According to internal data from Zoetis, AI Masses achieves high accuracy in identifying cellular abnormalities, streamlining workflows while maintaining clinical confidence.
The system leverages advanced deep learning algorithms to identify and categorize common lymph node and skin/subcutaneous masses. These insights are delivered at the point of care, enhancing accessibility to early cancer detection and helping veterinary teams personalize treatment plans with speed and precision. AI Masses is designed to integrate seamlessly into current clinic routines, using familiar sample preparation methods to avoid disruptions and preserve efficiency.
For added diagnostic assurance, clinics can also access expert clinical pathologist reviews through Digital Cytology and optional Add-on Expert Review services, typically available within hours. This layered approach to diagnosis offers an effective balance between the speed of AI technology and the interpretive strength of board-certified specialists.
According to Abhay Nayak, President of Global Diagnostics at Zoetis, AI Masses is more than just a tool for early cancer detection—it’s a way to support veterinary teams and alleviate stress for pet owners during some of the most challenging moments in the care journey.
“By empowering veterinary teams with valuable insights into potentially cancerous cells, we are helping to reduce waiting times and alleviate stress for pet owners,” Nayak said. “With comprehensive digital cytology capabilities and flexible result delivery options, Vetscan Imagyst AI Masses allows veterinary practices to make timely, individualized treatment decisions.”
Available now across North America, AI Masses reinforces Zoetis’ commitment to advancing animal health through innovation and precision diagnostics. The technology expands the utility of the Vetscan Imagyst platform, positioning it as a comprehensive solution for a broad range of in-clinic testing needs.
For more information about AI Masses and the full Zoetis diagnostics portfolio, visit zoetisdiagnostics.com/us.
References:
Zoetis Data on File. Study Report - DHXMZ-US-25-285
Zoetis Data on File. Study Report - DHXMZ-US-25-286
Data on File. TI-11711, 2024, Zoetis Inc.
Note: Vetscan Imagyst is the only commercially available analyzer currently offering seven distinct testing capabilities. Additional costs may apply for expert review services.
